Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Omega Therapeutics Inc (OMGA)

Omega Therapeutics Inc (OMGA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 78,872
  • Shares Outstanding, K 55,155
  • Annual Sales, $ 3,090 K
  • Annual Income, $ -97,430 K
  • 60-Month Beta 1.86
  • Price/Sales 24.24
  • Price/Cash Flow N/A
  • Price/Book 2.79
Trade OMGA with:

Options Overview Details

View History
  • Implied Volatility 297.97% ( +2.06%)
  • Historical Volatility 57.59%
  • IV Percentile 96%
  • IV Rank 52.35%
  • IV High 535.08% on 08/02/24
  • IV Low 37.48% on 05/13/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 19
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 1,452
  • Open Int (30-Day) 1,345

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.31
  • Number of Estimates 5
  • High Estimate -0.24
  • Low Estimate -0.40
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +22.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +22.13%
on 09/06/24
1.6100 -7.45%
on 08/23/24
-0.0700 (-4.49%)
since 08/19/24
3-Month
1.2200 +22.13%
on 09/06/24
2.6250 -43.24%
on 06/26/24
-0.7300 (-32.88%)
since 06/18/24
52-Week
1.2200 +22.13%
on 09/06/24
6.3000 -76.35%
on 01/04/24
-1.2600 (-45.82%)
since 09/19/23

Most Recent Stories

More News
Why Novo Nordisk Stock Crushed the Market Today

The company just boosted its research and development efforts.

NVO : 134.88 (+2.14%)
OMGA : 1.4800 (+3.50%)
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 30.90 (+0.46%)
FHTX : 9.66 (+1.05%)
MRNA : 68.05 (-2.59%)
OMGA : 1.4800 (+3.50%)
SANA : 4.59 (+6.99%)
MCRB : 1.0350 (-1.43%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFoundâ„¢ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 30.90 (+0.46%)
FHTX : 9.66 (+1.05%)
MRNA : 68.05 (-2.59%)
OMGA : 1.4800 (+3.50%)
SANA : 4.59 (+6.99%)
MCRB : 1.0350 (-1.43%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 30.90 (+0.46%)
FHTX : 9.66 (+1.05%)
MRNA : 68.05 (-2.59%)
OMGA : 1.4800 (+3.50%)
SANA : 4.59 (+6.99%)
MCRB : 1.0350 (-1.43%)
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business...

DNLI : 30.90 (+0.46%)
FHTX : 9.66 (+1.05%)
MRNA : 68.05 (-2.59%)
OMGA : 1.4800 (+3.50%)
SANA : 4.59 (+6.99%)
MCRB : 1.0350 (-1.43%)
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as...

DNLI : 30.90 (+0.46%)
FHTX : 9.66 (+1.05%)
MRNA : 68.05 (-2.59%)
OMGA : 1.4800 (+3.50%)
SANA : 4.59 (+6.99%)
MCRB : 1.0350 (-1.43%)
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act...

DNLI : 30.90 (+0.46%)
FHTX : 9.66 (+1.05%)
MRNA : 68.05 (-2.59%)
OMGA : 1.4800 (+3.50%)
SANA : 4.59 (+6.99%)
MCRB : 1.0350 (-1.43%)
Cellarity Strengthens Executive Leadership Team

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer...

IMPL : 0.0400 (-27.27%)
SELB : 0.8812 (-8.00%)
MDGN : 5.57 (+3.15%)
DNLI : 30.90 (+0.46%)
EVLO : 0.0001 (unch)
FHTX : 9.66 (+1.05%)
MRNA : 68.05 (-2.59%)
OMGA : 1.4800 (+3.50%)
SANA : 4.59 (+6.99%)
MCRB : 1.0350 (-1.43%)
Flagship Pioneering Unveils Ampersand Biomedicines to Create Highly Effective Medicines That Are Programed to Act Only Where Needed

Flagship Pioneering, the bioplatform innovation company, today unveiled Ampersand Biomedicines, a company creating programmable medicines that are safer, more tolerable, and effective by acting at the...

DNLI : 30.90 (+0.46%)
EVLO : 0.0001 (unch)
FHTX : 9.66 (+1.05%)
MRNA : 68.05 (-2.59%)
OMGA : 1.4800 (+3.50%)
SANA : 4.59 (+6.99%)
MCRB : 1.0350 (-1.43%)
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a multi-program agreement with Pioneering Medicines, a strategic initiative of Flagship Pioneering, that gives Pioneering Medicines...

CRL : 209.49 (+1.64%)
DNLI : 30.90 (+0.46%)
EVLO : 0.0001 (unch)
FHTX : 9.66 (+1.05%)
MRNA : 68.05 (-2.59%)
OMGA : 1.4800 (+3.50%)
SANA : 4.59 (+6.99%)
MCRB : 1.0350 (-1.43%)

Business Summary

Omega Therapeutics Inc. is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines. Omega Therapeutics Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 1.6533
2nd Resistance Point 1.5767
1st Resistance Point 1.5033
Last Price 1.4800
1st Support Level 1.3533
2nd Support Level 1.2767
3rd Support Level 1.2033

See More

52-Week High 6.3000
Fibonacci 61.8% 4.3594
Fibonacci 50% 3.7600
Fibonacci 38.2% 3.1606
Last Price 1.4800
52-Week Low 1.2200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar